The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

• Main Authors: Catherine G. Derington (Author), Adam P. Bress (Author), Jennifer S. Herrick (Author), Wenjun Fan (Author), Nathan D. Wong (Author), Katherine E. Andrade (Author), Jonathan Johnson (Author), Sephy Philip (Author), David Abrahamson (Author), Lixia Jiao (Author), Deepak L. Bhatt (Author), William S. Weintraub (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; a...